Katie M. O’Brien, Alexander P. Keil, Jack A. Taylor, Clarice R. Weinberg, Eric C. Polley, Siddhartha Yadav, Nicholas J. Boddicker, Chunling Hu, Christine B. Ambrosone, Hoda Anton-Culver, Paul L. Auer, Clara Bodelon, Kristen Brantley, Elizabeth S. Burnside, Fei Chen, Susan M. Domchek, A. Heather Eliassen, Christopher A. Haiman, James M. Hodge, Peter Kraft, James V. Lacey, Sara Lindstroem, Maria Elena Martinez, Katherine L. Nathanson, Susan L. Neuhausen, Janet E. Olson, Julie R. Palmer, Alpa V. Patel, Kathryn L. Penney, Kathryn J. Ruddy, Christopher G. Scott, Lauren R. Teras, Amy Trentham-Dietz, Celine M. Vachon, Jeffrey N. Weitzel, Song Yao, Gary Zirpoli, Fergus J. Couch, Dale P. Sandler
{"title":"Pathogenic Variants, Family History, and Cumulative Risk of Breast Cancer in US Women","authors":"Katie M. O’Brien, Alexander P. Keil, Jack A. Taylor, Clarice R. Weinberg, Eric C. Polley, Siddhartha Yadav, Nicholas J. Boddicker, Chunling Hu, Christine B. Ambrosone, Hoda Anton-Culver, Paul L. Auer, Clara Bodelon, Kristen Brantley, Elizabeth S. Burnside, Fei Chen, Susan M. Domchek, A. Heather Eliassen, Christopher A. Haiman, James M. Hodge, Peter Kraft, James V. Lacey, Sara Lindstroem, Maria Elena Martinez, Katherine L. Nathanson, Susan L. Neuhausen, Janet E. Olson, Julie R. Palmer, Alpa V. Patel, Kathryn L. Penney, Kathryn J. Ruddy, Christopher G. Scott, Lauren R. Teras, Amy Trentham-Dietz, Celine M. Vachon, Jeffrey N. Weitzel, Song Yao, Gary Zirpoli, Fergus J. Couch, Dale P. Sandler","doi":"10.1001/jamaoncol.2025.3875","DOIUrl":null,"url":null,"abstract":"ImportanceInherited pathogenic variants (PVs) in known predisposition genes can greatly increase breast cancer risk, but the combined impact of PV status, family history, and other factors on breast cancer risk in the general US population has not been well described.ObjectiveTo evaluate population-based breast cancer risk estimates for those with established PVs overall and stratified by first-degree family history of breast cancer and other factors.Design, Setting, and ParticipantsThis study used pooled data from 13 US-based breast cancer case-control studies participating in the Cancer Risk Estimates Related to Susceptibility (CARRIERS) consortium. Enrollment for individual studies occurred between 1976 and 2013, and results are based on data released March 2023, with analyses conducted from June 2022 to July 2025.ExposuresPVs, breast cancer family history, self-reported race and ethnicity, and established risk factors.Main Outcomes and MeasuresBreast cancer rate ratios for PVs in 7 genes were estimated from the CARRIERS consortium. PV status and incidence and mortality statistics were combined using the Individualized Coherent Absolute Risk Estimation (iCARE) model to estimate conditional cumulative breast cancer risks and 95% CIs, stratified by family history and standardized to the US population. Models that incorporated population-based data and published estimates for established epidemiologic risk factors were also evaluated.ResultsA total of 67 692 women were studied, including 33 841 who were diagnosed with breast cancer. PVs in <jats:italic>ATM</jats:italic>, <jats:italic>BRCA1</jats:italic>, <jats:italic>BRCA2</jats:italic>, <jats:italic>CHEK2</jats:italic>, and <jats:italic>PALB2</jats:italic> were strongly associated with breast cancer risk, with <jats:italic>BRCA1</jats:italic> and <jats:italic>PALB2</jats:italic> PVs showing evidence of heterogeneity by family history. In models considering PVs, family history, and established risk factors, the estimated cumulative risks of breast cancer by age 50 years ranged from 2.4% (95% CI, 2.4-2.4) in women with no PVs and no family history to 35.5% (95% CI, 21.6-55.1) in <jats:italic>PALB2</jats:italic> PV carriers with a family history. Among women who have not been diagnosed with breast cancer by age 50 years, the cumulative risk of breast cancer by age 80 years ranged from 11.1% (95% CI, 11.0-11.2) in noncarriers with no family history to 70.5% (95% CI, 52.8-83.5) for <jats:italic>PALB2</jats:italic> carriers with a family history. PV-specific cumulative risk estimates varied across subgroups defined by race and ethnicity and potentially modifiable epidemiologic risk factors.Conclusions and RelevanceIn this study, population-based estimates of cumulative breast cancer risk for established PVs, as informed by the CARRIERS case-control sample, varied by family history and potentially modifiable risk factors. These estimates provide guidance for identifying individuals who will most benefit from enhanced screening and prevention strategies.","PeriodicalId":14850,"journal":{"name":"JAMA Oncology","volume":"15 1","pages":""},"PeriodicalIF":20.1000,"publicationDate":"2025-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JAMA Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1001/jamaoncol.2025.3875","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
ImportanceInherited pathogenic variants (PVs) in known predisposition genes can greatly increase breast cancer risk, but the combined impact of PV status, family history, and other factors on breast cancer risk in the general US population has not been well described.ObjectiveTo evaluate population-based breast cancer risk estimates for those with established PVs overall and stratified by first-degree family history of breast cancer and other factors.Design, Setting, and ParticipantsThis study used pooled data from 13 US-based breast cancer case-control studies participating in the Cancer Risk Estimates Related to Susceptibility (CARRIERS) consortium. Enrollment for individual studies occurred between 1976 and 2013, and results are based on data released March 2023, with analyses conducted from June 2022 to July 2025.ExposuresPVs, breast cancer family history, self-reported race and ethnicity, and established risk factors.Main Outcomes and MeasuresBreast cancer rate ratios for PVs in 7 genes were estimated from the CARRIERS consortium. PV status and incidence and mortality statistics were combined using the Individualized Coherent Absolute Risk Estimation (iCARE) model to estimate conditional cumulative breast cancer risks and 95% CIs, stratified by family history and standardized to the US population. Models that incorporated population-based data and published estimates for established epidemiologic risk factors were also evaluated.ResultsA total of 67 692 women were studied, including 33 841 who were diagnosed with breast cancer. PVs in ATM, BRCA1, BRCA2, CHEK2, and PALB2 were strongly associated with breast cancer risk, with BRCA1 and PALB2 PVs showing evidence of heterogeneity by family history. In models considering PVs, family history, and established risk factors, the estimated cumulative risks of breast cancer by age 50 years ranged from 2.4% (95% CI, 2.4-2.4) in women with no PVs and no family history to 35.5% (95% CI, 21.6-55.1) in PALB2 PV carriers with a family history. Among women who have not been diagnosed with breast cancer by age 50 years, the cumulative risk of breast cancer by age 80 years ranged from 11.1% (95% CI, 11.0-11.2) in noncarriers with no family history to 70.5% (95% CI, 52.8-83.5) for PALB2 carriers with a family history. PV-specific cumulative risk estimates varied across subgroups defined by race and ethnicity and potentially modifiable epidemiologic risk factors.Conclusions and RelevanceIn this study, population-based estimates of cumulative breast cancer risk for established PVs, as informed by the CARRIERS case-control sample, varied by family history and potentially modifiable risk factors. These estimates provide guidance for identifying individuals who will most benefit from enhanced screening and prevention strategies.
期刊介绍:
JAMA Oncology is an international peer-reviewed journal that serves as the leading publication for scientists, clinicians, and trainees working in the field of oncology. It is part of the JAMA Network, a collection of peer-reviewed medical and specialty publications.